Pfizer gets FDA nod for Xeljanz to treat juvenile idiopathic arthritis

This article was originally published here

Xeljanz, claimed to be the first and only Janus kinase (JAK) inhibitor approved in the US to treat pcJIA, is available in two formulations such as a tablet

The post Pfizer gets FDA nod for Xeljanz to treat juvenile idiopathic arthritis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply